Alnylam Pharmaceuticals Inc. (ALNY) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Alnylam Pharmaceuticals Inc. (ALNY) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How ALNY Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $3.71B | 81.8% | 13.5% | $313.7M | $465.4M | 39.2% |
| FY 2024 | $2.25B | 86.4% | -7.9% | -$278.2M | -$42.6M | -14.3% |
| FY 2023 | $1.83B | 44% | -15.4% | -$440.2M | $21.9M | -2.9% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring ALNY)
- ✓Live walkthrough of ALNY's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
ALNY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +65.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ALNY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ALNY. Explore sector supply chains on /butterfly.
ALNY Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Alnylam Pharmaceuticals Inc. (ALNY)?
In FY 2025 (10-K), ALNY converted $3.7B of revenue into a 81.8% gross margin, 13.5% operating margin, and $465.4M in free cash flow (12.5% FCF margin).